Intra-Cellular Therapies, Inc. (ITCI) in Focus: Stock Rises 8.74% - Tale of the Tape - ANI Pharmaceuticals (NASDAQ:ANIP), Gilead Sciences (NASDAQ:GILD)

Intra-Cellular Therapies, Inc. (ITCI) was a big mover last session, as the company saw its shares rise nearly 9% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 17.56% in the past one-month time frame.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged. However, yesterday's price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Intra-Cellular Therapies currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other players in the healthcare industry include Illumina Inc. ILMN, Gilead Sciences Inc. GILD and ANI Pharmaceuticals, Inc. ANIP all carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

INTRA-CELLULAR (ITCI): Free Stock Analysis Report

ILLUMINA INC ILMN: Free Stock Analysis Report

GILEAD SCIENCES GILD: Free Stock Analysis Report

ANI PHARMACEUT ANIP: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs